Sale

Companies

Global Breast Cancer Treatment Market Share, Size, Growth: By Diagnosis: Imaging, Biopsy, Genomic Tests, Blood Tests, Others; By Therapy: Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy, Others; By Indication; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the breast cancer treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

 

  • Mylan N.V (Viatris Inc.)
  • AstraZeneca
     
  • Celltrion Inc.
  • Bristol-Myers Squibb Company
  • Fresenius Kabi AG
  • Eisai Co., Ltd.
  • Baxter
  • GSK plc
  • Pfizer Inc. 
  • Halozyme, Inc. 
  • Novartis AG

 

Breast Cancer Treatment  Drugs Market Report Snapshots

Breast Cancer Treatment  Drugs Market Size

Breast Cancer Treatment  Drugs Companies

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
2    Research Methodology
3    Executive Summary
4    Breast Cancer Overview

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Current Scenario Evaluation and Regulatory Framework
    6.1    Emerging Therapies and Clinical Trials
    6.2    Patent Landscape 
        6.2.1    Patent Overview
            6.2.1.1    Patent Status and Expiry
            6.2.1.2    Timelines from Drug Development to Commercial Launch
            6.2.1.3    New Drug Application
                6.2.1.3.1    Documentation and Approval Process
    6.3    Cost of Treatment
    6.4    Regulatory Framework
        6.4.1    Regulatory Overview
            6.4.1.1    US FDA
            6.4.1.2    EU EMA
            6.4.1.3    INDIA CDSCO
            6.4.1.4    JAPAN PMDA
            6.4.1.5    Others
7    Challenges and Unmet Needs
    7.1    Treatment Pathway Challenges
    7.2    Compliance and Drop-Out Analysis
    7.3    Awareness and Prevention Gaps
8    Global Breast Cancer Treatment Market
    8.1    Global Breast Cancer Treatment Market Overview
    8.2    Global Breast Cancer Treatment Market Analysis 
        8.2.1    Market Overview
            8.2.1.1    Global Breast Cancer Treatment Market Historical Value (2017-2023) 
            8.2.1.2    Global Breast Cancer Treatment Market Forecast Value (2024-2032)
        8.2.2    Global Breast Cancer Treatment Market by Therapy 
            8.2.2.1    Market Overview
                8.2.2.1.1    Targeted Therapy
                    8.2.2.1.1.1    Abemaciclib
                    8.2.2.1.1.2    Ado-Trastuzumab Emtansine
                    8.2.2.1.1.3    Everolimus
                    8.2.2.1.1.4    Trastuzumab
                    8.2.2.1.1.5    Ribociclib
                    8.2.2.1.1.6    Palbociclib
                    8.2.2.1.1.7    Pertuzumab
                    8.2.2.1.1.8    Olaparib
                    8.2.2.1.1.9    Others
                8.2.2.1.2    Hormonal Therapy
                    8.2.2.1.2.1    Selective Estrogen Receptor Modulators (SERMs)
                    8.2.2.1.2.2    Aromatase Inhibitors
                    8.2.2.1.2.3    Estrogen Receptor Downregulators (ERDs)
                8.2.2.1.3    Chemotherapy
                8.2.2.1.4    Immunotherapy
                8.2.2.1.5    Others
        8.2.3    Global Breast Cancer Treatment Market by Indication
            8.2.3.1    Market Overview
                8.2.3.1.1    Invasive Ductal Carcinoma
                8.2.3.1.2    Invasive Lobular Carcinoma
                8.2.3.1.3    Others
        8.2.4    Global Breast Cancer Treatment Market by Distribution Channel
            8.2.4.1    Market Overview
                8.2.4.1.1    Hospital Pharmacies
                8.2.4.1.2    Retail Pharmacies
                8.2.4.1.3    Online Pharmacies
                8.2.4.1.4    Others
        8.2.5    Global Breast Cancer Treatment Market by Region
            8.2.5.1    Market Overview
                8.2.5.1.1    North America
                8.2.5.1.2    Europe
                8.2.5.1.3    Asia Pacific
                8.2.5.1.4    Middle East and Africa
                8.2.5.1.5    Latin America
9    North America  Breast Cancer Treatment Market
    9.1    Market Share by Country
    9.2    United States of America
        9.2.1    Historical Trend (2017-2023)
        9.2.2    Forecast Trend (2024-2032)
    9.3    Canada
        9.3.1    Historical Trend (2017-2023)
        9.3.2    Forecast Trend (2024-2032)
10    Europe Breast Cancer Treatment Market
    10.1    Market Share by Country
    10.2    United Kingdom
        10.2.1    Historical Trend (2017-2023)
        10.2.2    Forecast Trend (2024-2032)
    10.3    Germany
        10.3.1    Historical Trend (2017-2023)
        10.3.2    Forecast Trend (2024-2032)
    10.4    France
        10.4.1    Historical Trend (2017-2023)
        10.4.2    Forecast Trend (2024-2032)
    10.5    Italy
        10.5.1    Historical Trend (2017-2023)
        10.5.2    Forecast Trend (2024-2032)
    10.6    Others
11    Asia Pacific Breast Cancer Treatment Market
    11.1    Market Share by Country
    11.2    China
        11.2.1    Historical Trend (2017-2023)
        11.2.2    Forecast Trend (2024-2032)
    11.3    Japan
        11.3.1    Historical Trend (2017-2023)
        11.3.2    Forecast Trend (2024-2032)
    11.4    India
        11.4.1    Historical Trend (2017-2023)
        11.4.2    Forecast Trend (2024-2032)
    11.5    ASEAN
        11.5.1    Historical Trend (2017-2023)
        11.5.2    Forecast Trend (2024-2032)
    11.6    Australia
        11.6.1    Historical Trend (2017-2023)
        11.6.2    Forecast Trend (2024-2032)
    11.7    Others
12    Latin America Breast Cancer Treatment Market
    12.1    Market Share by Country
    12.2    Brazil
        12.2.1    Historical Trend (2017-2023)
        12.2.2    Forecast Trend (2024-2032)
    12.3    Argentina
        12.3.1    Historical Trend (2017-2023)
        12.3.2    Forecast Trend (2024-2032)
    12.4    Mexico
        12.4.1    Historical Trend (2017-2023)
        12.4.2    Forecast Trend (2024-2032)
    12.5    Others
13    Middle East and Africa Breast Cancer Treatment Market
    13.1    Market Share by Country
    13.2    Saudi Arabia
        13.2.1    Historical Trend (2017-2023)
        13.2.2    Forecast Trend (2024-2032)
    13.3    United Arab Emirates
        13.3.1    Historical Trend (2017-2023)
        13.3.2    Forecast Trend (2024-2032)
    13.4    Nigeria
        13.4.1    Historical Trend (2017-2023)
        13.4.2    Forecast Trend (2024-2032)
    13.5    South Africa
        13.5.1    Historical Trend (2017-2023)
        13.5.2    Forecast Trend (2024-2032)
    13.6    Others
14    Global Breast Cancer Treatment Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Porter’s Five Forces Model 
    14.4    Key Demand Indicators 
    14.5    Key Price Indicators 
    14.6    Industry Events, Initiatives, and Trends 
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    Mylan N.V (Viatris Inc.)
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2    AstraZeneca
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications
    15.3    Celltrion Inc.
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    Bristol-Myers Squibb Company
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5    Fresenius Kabi AG
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6    Eisai Co., Ltd.
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7    Baxter
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8    GSK plc
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
    15.9    Pfizer Inc. 
        15.9.1    Company Overview
        15.9.2    Product Portfolio
        15.9.3    Demographic Reach and Achievements
        15.9.4    Mergers and Acquisitions
        15.9.5    Certifications
    15.10    Halozyme, Inc. 
        15.10.1    Company Overview
        15.10.2    Product Portfolio
        15.10.3    Demographic Reach and Achievements
        15.10.4    Mergers and Acquisitions
        15.10.5    Certifications
    15.11    Novartis AG
        15.11.1    Company Overview
        15.11.2    Product Portfolio
        15.11.3    Demographic Reach and Achievements
        15.11.4    Mergers and Acquisitions
        15.11.5    Certifications
16    Global Breast Cancer Treatment Market- Drug Distribution Model (Additional Insight)
    16.1    Overview 
    16.2    Potential Distributors 
    16.3    Key Parameters for Distribution Partner Assessment
17    Payment Methods (Additional Insight)
    17.1    Government Funded
    17.2    Private Insurance
    17.3    Out-of-Pocket

 

*Additional insights provided are customizable as per client requirements.

Key Questions Answered in the Report

The global breast cancer treatment market size reached a value of USD 22.49 billion in 2023.

The market is likely to grow at a rate of 10.10% during the forecast period of 2024-2032 to attain a value of about USD 53.47 billion by 2032.

Based on the therapy, the market is categorised into targeted therapy, hormonal therapy, chemotherapy, and immunotherapy, among others.

Based on the indication, the market is segmented into invasive ductal carcinoma and invasive lobular carcinoma, among others.

Based on the distribution channel, the market is categorised into hospital pharmacies, online pharmacies, and retail pharmacies, among others.

The different regions in the market are North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.

The key companies involved in the market are Mylan N.V (Viatris Inc.), AstraZeneca, Celltrion Inc., Bristol-Myers Squibb Company, Fresenius Kabi AG, Eisai Co., Ltd., Baxter, GSK plc, Pfizer Inc., Halozyme, Inc., and Novartis AG, among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER